Cannabidiol (CBD) and other cannabinoids play a significant role in the rescheduling debate. Unlike THC, CBD does not produce psychoactive effects and has been studied for its potential therapeutic benefits, including anti-inflammatory, analgesic, and anti-anxiety effects.
The increasing popularity and availability of CBD products, often marketed for health and wellness purposes, have further complicated the cannabis regulation landscape. The differentiation between CBD and other cannabinoids, particularly in terms of legal status and health effects, is an important aspect of the rescheduling conversation.
For more information on CBD and other cannabinoids, the World Health Organization provides a comprehensive report, available at WHO.int.
